Company intelligence / Profile preview
NantCell
Culver City, California, United Statesir.immunitybio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
NantCell has developed a broad immunotherapy pipeline targeting multiple tumor types using antibody, T cell, NK cell, cytokine fusion protein, mRNA, and vaccine modalities. The company’s lead program "Nogapendekin alfa inbakicept-pmln" received approval for non-muscle invasive bladder cancer. Other programs are advancing through Phase I/II clinical trials targeting solid tumors and infectious diseases. The company leverages advanced omics analytics to personalize therapy selection based on tumor proteomic/genomic profiles.[1][2][5][6]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodiesFusion proteinsCytokinesmRNA-based therapiesRecombinant vector vaccinesTherapeutic and prophylactic vaccinesChimeric Antigen Receptor (CAR) T cells and NK cells[1][2][5][6]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Amgen – exclusive rights deal for AMG479/Ganitumab monoclonal antibody except Japan [1].Celgene – investment partnership announced January 2019 [2].Key collaborations within the broader NantWorks ecosystem.
Beyond the preview
Go deeper on NantCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NantCell.